Please assess the completion status of the following clinical trial:

Trial Title: Effect of Olmesartan on Angiotensin(1-7) Levels and Vascular Functions in Diabetes and Hypertension

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* ≥ 30 years old~* Type 2 diabetes by American Diabetes Association criteria~* HbA1c: 6.5% ≤ - \< 10.0%~* Systolic blood pressure: 140 ≤ - \< 180 mmHg or Diastolic blood pressure: 85 ≤ - \< 110 mmHg~* Statin (-) or no change in low to moderate intensity statin \[14\] dose in recent 3 months~Exclusion Criteria:~* Contraindication of olmesartan or amlodipine~* History of RAS inhibitors (ACE inhibitors or ARBs) or calcium channel blockers in the previous 3 months~* Pregnant women, women with potential of pregnancy not using adequate contraception method as evaluated by the investigator, lactating women~* Type 1 diabetes or diabetes secondary to chronic pancreatitis or to pancreatectomy~* Confirmed cardiovascular disease (acute coronary syndrome, stroke, or transient ischemic attack) within 3 months of screening~* Chronic hepatitis B or C (except healthy carrier of HBV), liver disease (AST/ALT \> 3-fold the upper limit of normal)~* Chronic kidney disease (serum creatinine \> 2.0 mg/dL)~* Hyperkalemia serum potassium \>5.0 mEq/L~* Any previous cancer within 5 years (except squamous cell cancer, cervical cancer, thyroid cancer with appropriate treatment) except thyroid cancer or carcinoma in situ

- Gender: ALL
- Minimum Age: 30 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Olmesartan (Type: EXPERIMENTAL): - Olmesartan group: Olmesartan, 20 (40) mg once a day, oral administration
- Amlodipine (Type: ACTIVE_COMPARATOR): - Comparator group: Amlodipine, 5 (10) mg once a day, oral administration

Based on this trial design, predict the completion outcome and termination type (if applicable).